Abstract
This community-based cross-sectional study investigates the seroprevalence of the Hepatitis C Virus (HCV) and its associated demographic and behavioral risk factors among the men who have sex with men (MSM) in Pakistan. The study reveals an HCV seroprevalence of 14.86%, significantly higher than global averages for the MSM population. Notably, HCV seroprevalence was associated with age, education level, self-identified sexual orientation, and self-reported HIV status. Furthermore, the study identified several risk factors positively associated with HCV seroprevalence, including sharing personal items such as razors and toothbrushes, histories of surgery, blood transfusion, dental procedures, intravenous drug use, and therapeutic injection histories. Interestingly, a lower HCV positivity rate was observed among self-reported HIV-positive individuals, contradicting previous research. The findings underscore the need for comprehensive, targeted prevention strategies tailored to the MSM population in Pakistan. Further research is warranted to validate these findings and to understand better the complex interplay of factors contributing to HCV seroprevalence in this high-risk population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Bioethics Committee of the Cancer Research Centre, University of the Punjab gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
